FDA Recommends Inclusion of BA.4, BA.5 Subvariants in COVID Boosters

Published on June 30, 2022

The FDA is urging COVID-19 vaccine manufacturers to revamp their booster shots to specifically target the prevalent omicron BA.4 and BA.5 subvariants. It’s like tweaking a recipe to include additional ingredients that fight the new iterations of coronavirus! This adjustment will enhance the effectiveness of the boosters against these emerging subvariants and better protect individuals from potential infection. By tailoring the components of the boosters, scientists are essentially upgrading the defense mechanism against the virus, much like adding specialized weapons to an arsenal to counteract evolving threats. With research indicating that the omicron variant may have increased immune evasion abilities than previous variants, incorporating these subvariants into boosters is a proactive measure to stay one step ahead in the ongoing battle against COVID-19. To learn more about this FDA recommendation and its implications on vaccine effectiveness, check out the article!

The U.S. Food and Drug Administration on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant omicron BA.4 and BA.5 subvariants of the coronavirus.If…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>